Unilabs has signed an agreement with AI provider Mindpeak, further bolstering its breast cancer offering

 Unilabs, the leading diagnostic services provider, has signed an agreement with Mindpeak, an AI solutions provider for digital pathology.

Mindpeak’s AI technology will speed up breast cancer screening and make it more accurate.

“At Unilabs, we are continuously improving the quality and efficiency of our diagnostics capabilities by investing in the best available technology,” said Unilabs Chief Medical and Operations Officer Dr Christian Rebhan. “This development will transform the way pathologists work and will allow us to better serve our customers.”

The deployment has started at Unilabs St Göran’s lab in Stockholm, with the first cases read. The technology will be progressively rolled out in other parts of Sweden before being deployed in other Unilabs’ countries.

“This development will transform the way pathologists work and will allow us to better serve our customers.”

Diagnosing breast cancer involves the detection and quantification of immunohistochemically stained breast tumour cells, a critical task that is currently done manually, and takes a lot of time. Mindpeak AI helps pathologists count these cells, cutting reporting time by an estimated 60% and ensuring results can be reproduced to the same quality on every occasion.

One of the most critical factors with breast cancer is time.

For patients, the integration of Mindpeak means faster diagnosis. And of course the sooner the treatment can begin, the better the prognosis.

“We are very pleased that Unilabs, one of the world’s largest diagnostics groups, chose our state-of-the-art AI-based diagnostic tools. Deep workflow integration of our AI tools will deliver significant efficiency gains and ultimately save lives,” said Felix Faber, CEO of Mindpeak.